This article reports what published trial data, individual patient data meta-analyses, and clinical guidelines describe about lipid changes on testosterone replacement therapy. It is not medical advice. TRT requires a licensed prescriber for individual risk assessment, monitoring, and any dose or medication changes.
The cholesterol question follows men into TRT clinics every week. Will this lower my HDL? Will my LDL spike? Should I be worried if my lipid panel shifts? The published evidence is more reassuring and more nuanced than forum culture suggests. Testosterone replacement therapy at physiologic doses produces small, predictable lipid changes — typically a modest HDL decrease, broadly neutral LDL, and neutral-to-slightly-improved triglycerides. The TRAVERSE trial confirmed those shifts do not translate into excess cardiovascular events over 33 months of follow-up. This page describes what the trial and meta-analytic data actually show, why the changes happen, who is most susceptible, and how a disciplined TRT clinic builds lipid monitoring into the standard workup.
If your HDL has dropped on TRT and you are trying to figure out whether the change is normal, concerning, or actionable, this is the reference page.
What the Trial Data Shows
Three datasets dominate the published evidence base on TRT and lipids: the TRAVERSE trial, the Hudson individual patient data meta-analysis from Lancet Healthy Longevity, and the older but still-cited transdermal-versus-injectable trials. The picture they paint is consistent.
TRAVERSE — modest lipid shifts, neutral cardiovascular endpoint
TRAVERSE (Lincoff et al., NEJM 2023) randomized 5,246 men aged 45-80 with hypogonadism and pre-existing or high-risk cardiovascular disease to daily transdermal testosterone gel 1.62% or matching placebo, with a mean follow-up of about 22 months and a maximum of 33 months. The primary safety endpoint — death from cardiovascular causes, nonfatal MI, or nonfatal stroke — was non-inferior in the testosterone arm. Secondary lipid measurements showed small between-group shifts: HDL was modestly lower in the testosterone arm, with broadly neutral changes in LDL and triglycerides at the time points reported. Glycometabolic control and blood pressure remained stable across groups.
The trial result that drove the February 2025 FDA labeling change was the neutral cardiovascular composite, not the lipid shifts. The lipid changes were within the size described in earlier meta-analyses and were judged clinically minor in light of the neutral cardiovascular endpoint.
Hudson IPD meta-analysis — modest HDL decrease confirmed
Hudson et al. (Lancet Healthy Longevity 2022) pooled individual participant data from 17 randomized trials (1,750 testosterone-arm participants and 1,681 placebo-arm participants) with aggregate data from 18 additional trials. The analysis found no significant excess in cardiovascular events or mortality on testosterone therapy in the short-to-medium term. The detected lipid signal was a modest lowering of total cholesterol and HDL cholesterol on testosterone versus placebo. The authors framed the HDL decrease as the principal lipid effect of TRT in pooled trial data.
This is the highest-quality lipid synthesis available — individual patient data with consistent extraction methodology — and it broadly aligns with TRAVERSE.
Cai et al. T2DM meta-analysis — direction depends on baseline
Cai et al. (European Journal of Endocrinology 2017) ran a focused meta-analysis of testosterone supplementation in hypogonadal men with type 2 diabetes. The HDL-C change differed by population: a small HDL increase was reported in some cohorts (developing-country studies), with no consistent improvement in others. LDL changes were not consistently directional. The take-away is that lipid response on TRT depends on baseline metabolic state — men with metabolic syndrome and low baseline HDL respond differently from healthy hypogonadal men with already-normal lipids.
Why Testosterone Changes Lipids
Several mechanisms have been described in the published literature. The HDL effect is the best characterized.
Hepatic lipase upregulation (the HDL story)
Androgen-receptor activation in the liver upregulates hepatic lipase, an enzyme that catabolizes HDL particles. Higher hepatic lipase activity speeds HDL clearance from circulation, which lowers the steady-state HDL number on a fasting lipid panel. The effect is dose-dependent: physiologic-replacement testosterone produces a small HDL decrease, while supraphysiologic anabolic-steroid doses produce a much larger one. This dose-response is part of why physician-managed TRT trials show small HDL drops while case reports of recreational anabolic-steroid use show 30-50% HDL suppression.
The hepatic-lipase mechanism explains why oral testosterone formulations historically produced larger lipid effects than transdermal or injectable testosterone — first-pass hepatic exposure amplifies the enzyme upregulation. Modern oral testosterone undecanoate is dosed to minimize first-pass exposure and produces a smaller lipid signal than older 17α-alkylated oral androgens.
Body composition changes (the LDL and triglyceride story)
Testosterone shifts body composition — lean mass up, fat mass typically down — and improves insulin sensitivity in many men. These changes tend to nudge LDL and triglycerides in a favorable direction. The net LDL effect on TRT is broadly neutral in trial populations because the body-composition benefit and the hepatic-lipase effect partially offset each other for non-HDL particles. Triglycerides typically follow the body-composition trajectory and are neutral-to-slightly-improved on average.
Insulin sensitivity and metabolic syndrome
A meaningful subset of men starting TRT have baseline metabolic syndrome — elevated triglycerides, low HDL, abdominal adiposity, and insulin resistance. In this subgroup, the body-composition and insulin-sensitivity benefits of TRT can produce favorable lipid changes that exceed the hepatic-lipase HDL drop. This is the population where some studies report HDL increases or favorable triglyceride changes despite the canonical "TRT lowers HDL" narrative.
Ester, route, and dosing frequency
Transdermal testosterone (gel, patch) avoids the supraphysiologic injection peaks and produces smaller HDL changes on average than once-weekly intramuscular cypionate or enanthate. Within injectables, more frequent dosing (twice-weekly or every-other-day subcutaneous) smooths the peak-trough curve and may produce smaller lipid swings than once-weekly intramuscular at the same total weekly dose. The mechanistic explanation is the same as for hematocrit and blood pressure — lower peaks generally mean smaller downstream physiologic shifts.
Who Sees the Largest Lipid Changes
The published data and clinic experience converge on a short list of men who tend to see larger HDL or LDL movement on TRT.
| Risk factor | Why it matters |
|---|---|
| Higher TRT dose / supraphysiologic levels | Hepatic lipase upregulation is dose-dependent; bigger doses, bigger HDL drop |
| Once-weekly intramuscular dosing | Larger peak-trough swings produce larger lipid swings than daily transdermal or every-other-day SC |
| Oral androgens (especially 17α-alkylated, historical) | First-pass hepatic exposure amplifies lipid effects; modern oral T undecanoate less affected |
| High baseline HDL | Mathematically, more room to drop; men with HDL of 70 mg/dL show larger absolute changes than men with HDL of 35 mg/dL |
| Pre-existing metabolic syndrome | Lipid response is more variable; some men improve, others worsen |
| Concurrent anabolic-steroid use | Stacking exogenous androgens dramatically amplifies hepatic lipase signaling |
A man on a standard physiologic-dose TRT protocol (100-160 mg testosterone cypionate per week, split into twice-weekly injections, monitored by a licensed prescriber) is unlikely to see a clinically meaningful adverse lipid change. A man on a supraphysiologic 300+ mg/week regimen with concurrent anabolic-steroid use is in a fundamentally different lipid risk category and the TRAVERSE-era reassurance does not apply.
What Disciplined Clinic Monitoring Looks Like
A clinic that takes lipid monitoring seriously builds it into the workup rather than waiting for symptoms.
Baseline
- Fasting lipid panel (total cholesterol, LDL, HDL, triglycerides) at the initial consult, alongside the standard hormone and CBC workup.
- ApoB and Lp(a) where the clinical picture warrants — particularly for men with a personal or family history of premature cardiovascular disease.
- Documentation of any current lipid-lowering therapy (statins, ezetimibe, PCSK9 inhibitors) and adherence.
- For men with frank dyslipidemia or known atherosclerotic disease, treating to lipid goals before or alongside starting TRT is the conservative approach described in published guidelines.
3-6 month recheck
- Repeat fasting lipid panel alongside the standard trough total testosterone, free testosterone, estradiol, and CBC.
- A meaningful HDL drop (>10 mg/dL) at 3-6 months is a signal to recheck on a separate fasting draw rather than dismissing as noise.
- The lipid trend gets reviewed in the context of the hematocrit, body composition, and overall cardiovascular picture — not as an isolated number.
Ongoing monitoring
- Annual fasting lipid panel for stable patients on stable doses, integrated with the rest of the TRT bloodwork schedule.
- Re-evaluation of statin or other lipid-lowering therapy needs based on the on-TRT lipid pattern, not the pre-TRT pattern.
- Closer monitoring (every 6 months) for men with baseline dyslipidemia, established cardiovascular disease, or larger-than-expected lipid responses early in therapy.
The TRT bloodwork schedule describes the broader monitoring cadence; the lipid panel fits into that schedule as a standard quarterly-to-annual check, not a once-and-forgotten baseline.
What to Do When Lipids Move on TRT
The published literature and clinic experience describe a stepwise workup when the lipid panel shifts meaningfully on TRT.
Step 1: Confirm the shift
A single lipid panel is not a trend. Repeat the panel on a separate fasting draw (true 12-hour fast, no recent illness, no recent alcohol binge, no acute stressor) before drawing conclusions. Lipid panels carry meaningful biological and lab variability, and one outlier reading should be confirmed before changing any treatment.
Step 2: Put the change in context
A 5 mg/dL HDL drop in a man whose total cardiovascular risk profile is otherwise improving — better insulin sensitivity, lower visceral fat, lower blood pressure, better fitness — is not the same risk story as the same number in a man who is also gaining weight, sleeping poorly, and seeing his hematocrit climb. Lipid panels are inputs to a multi-variable cardiovascular picture, not standalone verdicts.
Step 3: Evaluate the obvious upstream factors
- Diet changes since starting TRT (often weight gain in early months drives lipid changes more than testosterone itself does)
- Alcohol intake changes
- Activity level changes
- New medications affecting lipids (corticosteroids, certain beta-blockers, retinoids)
- Concurrent anabolic-steroid use (a separate problem from prescribed TRT)
Step 4: Consider dose, ester, and protocol changes
If the lipid panel has moved adversely on TRT and other factors are controlled, the literature describes several levers:
- Lower the testosterone dose to bring trough levels into the lower half of the target range rather than the upper half. Hepatic lipase response is dose-dependent.
- Switch from once-weekly intramuscular to twice-weekly or every-other-day subcutaneous dosing to smooth peaks. See injection frequency: weekly vs every-other-day and subcutaneous vs intramuscular TRT for the mechanics.
- Consider transdermal testosterone if injectable lipid response is large and patient-acceptable to switch — the gel ABPM and lipid data show smaller average lipid shifts than injectable cypionate.
Step 5: Treat the dyslipidemia if it persists
Most men with sustained, confirmed adverse lipid changes on TRT can stay on therapy with the addition or escalation of standard lipid-lowering treatment (statin first-line, ezetimibe or PCSK9 inhibitor as second-line per the clinical picture). The decision to add or escalate lipid-lowering therapy belongs to the prescribing clinician and follows the same algorithm as in any patient with dyslipidemia — TRT does not change the underlying treatment ladder.
Step 6: Discontinue TRT only if the lipid picture is uncontrollable
The literature does not support reflexive TRT discontinuation for a 5-10 mg/dL HDL drop. It does support discontinuation for severe, uncontrollable lipid abnormalities or for an individual whose risk-benefit picture has shifted unfavorably. This is a prescriber-level decision, not a forum-level decision.
How Clinics Vary on This
Not every TRT clinic monitors lipids at the standard above. The patterns we have seen across the TRT clinic comparison hub:
- Disciplined clinics: Order a fasting lipid panel at baseline, repeat at 3-6 months and annually thereafter, integrate the lipid picture with hematocrit, body composition, and blood pressure, and coordinate with primary care or cardiology when lipid-lowering therapy is needed. These clinics earn high marks on the monitoring dimension of the scoring methodology.
- Adequate clinics: Order a baseline lipid panel and recheck only if the patient asks or has obvious cardiovascular risk factors. Catch most major problems but miss subtle drift.
- Weak clinics: Do not order a baseline lipid panel and do not check lipids during follow-up unless the patient drives the request. This pattern shows up in TRT clinic red flags.
A clinic that is willing to push your testosterone dose into the upper end of the reference range without monitoring lipids, hematocrit, or blood pressure is not managing TRT to a clinical standard. The questions to ask a TRT clinic page lists the specific monitoring questions worth asking before signing up.
Common Misreadings
Forum culture tends to misread the lipid question in two directions, both wrong.
- "TRT does not affect cholesterol." It does. The Hudson IPD meta-analysis and TRAVERSE both report measurable HDL changes on testosterone versus placebo. The effect is small but real, and pretending it is zero is not consistent with the evidence.
- "TRT destroys HDL and causes heart disease." It usually does not. The mean HDL effect is a few mg/dL, well within the range that standard cardiovascular management handles, and the TRAVERSE primary cardiovascular endpoint was neutral over 33 months. Most men with controlled lipids can take TRT safely with monitoring.
The honest reading is the one in the middle: TRT lowers HDL by a small amount on average, has neutral effects on LDL and triglycerides, and the changes are mostly manageable with good monitoring and standard lipid-lowering therapy when needed.
Bottom Line
Testosterone replacement therapy lowers HDL cholesterol by a small amount on average — typically 2-6 mg/dL versus placebo in trial populations — with broadly neutral effects on LDL and triglycerides. The TRAVERSE trial confirmed those modest lipid shifts do not translate into excess cardiovascular events over 33 months of follow-up, which informed the FDA's February 2025 removal of the older cardiovascular boxed warning from testosterone product labels. The clinical implication is not "do not start TRT" — it is "monitor lipids at baseline, at 3-6 months, and annually thereafter, treat dyslipidemia to standard goals when it persists, and choose a clinic that takes the monitoring seriously." A disciplined TRT clinic builds lipid monitoring into every annual visit, manages adverse lipid changes with the same algorithm used for any patient with dyslipidemia, and does not push doses past the level your overall cardiovascular picture can handle.
Related Reading
- TRT Bloodwork Schedule: What to Test and When
- TRT and Blood Pressure: What the Data Shows (2026)
- TRT Polycythemia and Hematocrit Management
- TRT Cardiovascular Risk: TRAVERSE Trial
- European Panel TRT Cardiovascular Position Statement (2026)
- Injection Frequency: Weekly vs Every Other Day
- Best Online TRT Clinics 2026